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Objective: To evaluate the prevalence of class-specific antibodies (G, A, M) to Yersinia enterocolitica plasmid-encoded 
outer proteins (Yops), in a closely followed multitransfused population of patients with thalassemia. 
Methods: Sera from 408 P-thalassemic patients and 386 healthy blood donors used as controls were analyzed with the 
enzyme-linked immunosorbent assay (ELSA) for IgG, IgA and IgM antibodies to yersinia outer proteins. The Yop antigen 
for the ELISA was prepared using a plasmid-bearing wild-type strain of Y enterocolitica of serotype 0:8. 
Results: Anti-Yop IgG antibodies were detected in 84 out of 408 P-thalassemic patients (20.6%) compared with only 
eight out of 386 (2.1%) healthy blood donors. None of the sera of either group was positive for anti-Yop IgA or IgM 
antibodies. On evaluating patients with registered clinical and laboratory signs of a previous yersinia infection in the 
period from 1978 t o  1996, we found that those with a positive agglutination test for Y enterocolitica infection at the time 
of manifestation showed a higher rate of persisting IgG seropositivity t o  Yops than those with positive culture and clinical 
signs only. A significant percentage (9.49%) of the seropositive patients had no registered data of a past Y enterocolitica 
infection. There was remarkable persistence of anti-Yop IgG antibodies in the thalassemic population, even in  patients 
infected during the early years of our study period (1978-80). 
Conclusions: The results suggest that the determination of class-specific antibodies to Yops, which are specific antigens 
for the pathogenic yersiniae ( Y  enterocolitica, Y pseudotuberculosis and Y: pestis), in addition to  its usefulness in the 
diagnosis of infection, wi l l  be a very sensitive and specific index for epidemiologic studies. 
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INTRODUCTION 
12vsiriiil entevcmditiw is recognized worldwide as a cause 
of human enteric infections [1,7]. In Europe and 
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Japan, human infections occur most frequently with 
serotypes 03:biotype IV and 0'9:biotype 11, whervas 
in the USA serotype 08:biotype I1 is the most 
common cause of enteric infection [3,4]. All human 
pathogenic yersiniae (I: entcvorolitira, 1: pserido- 
ttrhevrt.rfosis and I: pcsfis) harbor a 70-75-kb plasniid 
which is essential for virulence expression. More than 
20 plasniid-encoded polypeptides have been identified 
[5,6]; these are proteins secreted into the culture 
medium (yersinia outer proteins) (Yops), outer- 
membrane proteins (YadA) and tytosolic proteins. The 
regulation and expression of the responsible encoding 
genes for these proteins depends on several factors, 
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such as temperature and the calcium concentration of 
the culture medium [5-71. Plasmid-mediated viru- 
lence is expressed as resistance to serum bactericidal 
activity, resistance to phagocytosis, cell adhesion and 
cytotoxicity. In addition to the plasmid-encoded 
factors, several chromosomal virulence determinants 
exist, principally two invasins, one heat-stable entero- 
toxin (Yst) [8] and one iron-utilization system. The 
latter is composed of three determinants, the sidero- 
phore yersiniabactin, the membrane receptor FyuA 
and the siderophore export-import system [9]. 
Iron accumulation has been shown to be a very 
important predisposing factor for I.: erztevocoliticu. These 
bacteria are capable of taking up siderophores which are 
also produced by other bacteria, such as desferri- 
oxamine B (DFOB), an iron-chelating compound 
produced by Streptomyces pilosus which is used thera- 
peutically in cases with acute or chronic iron overload. 
Therapy with DFOB may increase the risk of fulminant 
1: eritevocolitica infection [10-17]. 
I n  Greece, yersinia infection in multitransfused 
patients with thalassemia is quite common. During the 
years 1977-85, Y etzterocoliticu infection was diagnosed 
in 10% of the regularly transfused patients at the 
thalassemia unit of the University Department of 
Pediatrics [18]. In this study, in addition to clinical 
diagnosis and stool and blood culture, detection of 
antibodies to I.? erzterocoliticu by agglutination was a 
useful diagnostic tool. However, diagnosis of the 
chronic and more compIicated forms ofthe disease may 
be very difficult [19,20], as stool culture and conven- 
tional serology may be negative after the acute phase 
In 1986 new methods were introduced, such as the 
determination of class-specific serum IgA, IgM and 
IgG antibodies against the Yops 11211 using the 
immunoblot or the enzyme-linked immunosorbent 
assay (ELISA). As Yops are unique antigens of patho- 
genic yersiniae, the detection of class-specific 
antibodies proved to be more sensitive and specific than 
the routine agglutination test [Z], with 83% and 18% 
sensitivities and 82% and 29% specificities, respectively. 
IgA, IgM and IgG antibodies appear early in the acute 
phase. The persistence of IgA antibodies more than 2 
years after infection is associated with a persistent 
chronic form. The presence of IgG antibodies only 
indicates a past cleared infection. In the present study, 
the prevalence of class-specific antibodies to the Yops 
in a population of multitransfused patients with 
thalassemia followed at the thalassemia unit of the 1st 
Department of Pediatrics, Athens University, including 
some with diagnosed and treated I: enterocoliticu 
infection, was investigated. 
1191. 
PATIENTS AND METHODS 
Patients’ sera 
Four hundred and eight serum samples from multi- 
transfused P-thalassemic patients (aged 7-40) and 386 
serum samples from healthy blood donors (matched 
controls) were collected in 1997 for the determination 
of class-specific antibodies to Yops. Each P-thalassemic 
serum sample was accompanied by a report form, 
containing the patient’s personal data, history of 
previous yersinia infection, clinical signs, laboratory 
examination results (culture, agglutination test (Sanofi 
Diagnostics Pasteur, Marnes-la-Coquette, France), ultra- 
sonogram) and treatment. Sera were kept frozen at 
-20°C until the date of antibody determination. 
Preparation of the Vop antigens for the ELISA 
Isolation of the plasmid-encoded outer proteins of k: 
enterocoliticu was performed as described previously [23]. 
An overnight culture, at 27OC on blood agar plates, of 
a Y enterocoliticu serotype 0 : 8  plasmid-bearing wild- 
type strain WA pYV,AO,KnR (kanamycin resistant, 
YadA negative; kindly provided by Professor J. 
Heesemann, Institute of Hygiene and Microbiology, 
Munich, Germany) was used to inoculate 5 mL of 
brain-heart infusion broth (Difco Laboratories, 
Detroit, USA) containing 50 mg/L kanamycin (Sigma, 
Deisenhofen, Germany). After overnight incubation at 
27°C with agitation (120 revlmin), the broth was 
diluted 120 with fresh brain-heart infusion broth and 
then incubated with agitation at  37OC for 90 min. 
Finally, 5 mM EGTA, 15 mh4 MgClz and 0.2% glucose 
were added, and the incubation with agitation was 
continued for a further 2 h at 37°C. Bacteria were then 
separated by centrifugation (8000g) and the supernatant 
containing the Yops was stored in 1-ml amounts at  
-20°C for further use as an antigen in the ELISA. 
Enzyme-linked immunosorbent assay (ELISA) 
The ELISA for the detection of anti-Yop antibodies 
was performed as described elsewhere [24] with 
modification as follows. 
In each test, 100 pL of the Yop antigen preparation 
diluted 1 : l O  in a standard coating buffer (Na2C03/ 
NaHCOz, pH 8.5) was applied to a flat-bottomed 
microELISA plate (Costar, USA) which was then in- 
cubated overnight at  4°C. The plate was rinsed three 
times with phosphate-buffered saline (PBS)/O.5% 
Tween-20, and then blocked by incubation for 1 h at 
37°C with 150 pL PBS/0.5% Tween-20/5% bovine 
serum albumin. After three rinses with PBS/Tween-20, 
150 pL of patient’s serum, diluted 1: lOOO in PBS/ 
Tween-20, was added to the plate, which was then 
incubated for 2 h at 37°C. After three rinsings, 100 pL 
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of peroxidase-conjugated goat antihuman inimuno- 
globulin (Sigma) was added, in final dilutions (PBS/ 
Tlveen-20) of 1:3000 for IgG, and 1:2000 for IgA and 
IgM, and the plate was incubated for 1 h at 37OC. After 
six rinsing steps, 100 pL of freshly prepared substrate 
(40 nig o-yhenylenedianiine+S pL 30% HzOz in 
12 niL standard buffer citric acid/NalHPO1, pH 5.0; 
Sigma) was added, and after 20 niin of incubation at 
room temperature, the reaction was stopped with 
100 pL 0.25 M H2SOq. The OD of the colored 
product was measured at 492 nm with an  ELISA reader. 
All sera, including positive and negative controls, were 
run in duplicate. O n  each plate, 13 sera from normal 
healthy individuals were tested and served for the 
determination of the cut-off' value, which was 
calculated as the mean -+2 standard deviations (SD). 
RESULTS 
The determination of class-specific antibodies to Yops 
gave a 10-fold higher prevalence of positive IgG in the 
P-thalassemic patients (84 of 408: 20.58%) than in the 
control group of healthy blood donors (8 of 386: 
2.t17'81) (Table 1). No positive sera for IgA and IgM 
antibodies were detected in either group. In order to 
correlate the results with previously diagnosed 1: 
crzteuocoliticu infection, the P-thalassemic patients were 
divided into five groups according to the clinical and 
laboratory data obtained (Table 2). Group 1 included 
patients with a positive agglutination test, a positive 
Table 1 Prevalence of IgG antibodies to yersinia outer 
proteins (Yops) in inultitransfused patients with thaldsseniia 
and in healthy blood donors (control group) 
Subjects IgG positive IgC negative Total 
All thalarscmic patient$ 84 (ZO.h'!u) 321 (70.4"7)) 408 
I'reviourly diagnosed 53 (h5.1u,l) 28 (34.6'!,0) 81 
as having yersitiia 
infection 
No previouc yersinia 31 (9.54~) 2% (90.5"%) 377 
infection documented 
Controls (blood doiiorc) 8 ('.loo) 378 (97.Y"o) 3% 
stool or blood culture and two or more of the clinical 
signs of fever, abdominal pains, diarrhea, vomiting, 
palpable mass of the right iliac fossa, joint pains, rash, 
arthritis or ultrasonographic abdominal findings. 
Group 3 represented patients with a positive culture, 
clinical findings and a negative agglutination test. 
Group 3 coniprised patients with a positive agglutin- 
ation test and clinical features but a negative culture. 
Group 4 was composed of patients with only clinical 
signs suggestive of a yersinia infection, and group 5 
comprised the remainder of the P-thalassemic indivi- 
duals presenting no yersinia infection. The classical 
agglutination test represented antibodies to serotype 
0 : 3 ,  which is the most coninion pathogenic serotype 
of I: entevocolitiril found in Greece. 
In all groups there was a remarkable seropositivity 
to Yops IgG. The score was highest in group 1 (84.2'>0), 
Table 2 I'revalcncc of IgG antibodies to yersinia outer proteins (Yops) in niultitransfused P-thalesseiriic patients in the first 
trimester of 1997 as thcy re l~ te  to clinical or laboratory signs ofprevious 1: wtmxolificcl infection between 1978 and 1996 
Positive Ncgative 
Clinical' or laboratory cigns anti-Yop IgG anti-Yop IgG Total 
Positive agglutination test and positive stool or 16 (81.2'%>) 3 (15.8"h) 1 0 
Group 1 
blood culture and rlinical signs 
Group 2 
Only positive culture and clinical signs 
Group 3 
Only a poritive agglutination trrt 
and clinical signs 
3 (42.9%) 






Only clinical signc 7 (43.8YO) 9 (56.3%) 16 
Group 5 
N o  known signs 31 ( 9 . 5 ? i )  29b (90.5"4 327 
Total 81 324 408 
'Fever, abdominal pains, diarrhea, vomiting, pseudoappendicitis, joint pains, rash, abdorninnl 
mass, nephritis, arthritis, splenic absccss, ultrasonographic abdominal findings. 
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Table 3 Prevalence of IgG antibodies to yersinia outer 
proteins (Yops) in multitransfused P-thalassemic patients in 
thc first trimester of 1997 according to the period in which 
the yersinia infection was diagnosed. Patients included 
groups 1, 2 and 3 froni Table 2 
Period in which Anti-Yop Anti-Yop 
infection was IgG-positive IgG-negative 
























20 (30.8%) 65 
followed by group 3 (69.2%), which indicates that 
people reacting with positive antibodies in the classical 
agglutination test retain, in general, a long-lasting 
immunological reaction to Yops. The prevalence of 
9.5% (total 327) in group 5 was remarkable; this group 
comprised P-thalassemic patients with no previously 
documented yersinia infection during the time of their 
follow-up at the unit. 
However, as only patients belonging to groups 1, 
7 and 3 were medically confirmed cases of 1; 
erztevocoliticu infection, we further divided these people 
into groups according to the 3-year period in which 
the yersinia infection was diagnosed (Table 3). Among 
the total of 65 patients, 46 (70.8%) were still positive a t  
the time of testing for class-specific antibodies (1997). 
From 1978 to 1992, the number of positive patients 
varied from period to period without any significant 
correlation with time. However, patients with an 
infection first diagnosed from 1993 to 1996 were 
almost all still positive for anti-Yop IgG antibodies 
(except for one case in the period from 1993 to 1995; 
Table 3). 
DISCUSSION 
The experience gained at our thalassemia unit an  I.: 
erztcvocolitica infection has already been reported, with a 
rate of infected patients rising to 10% of all who were 
followed up regularly [38]. However, the prevalence of 
class-specific IgG antibodies to Yops was much higher: 
70.6% of all P-thalassemic patients included in our 
study and 10-fold higher than that in healthy blood 
donors (Tables 1 and 2). 
Although the main predisposing cause of the 
P-thalassemic patients' susceptibility to 1: enterocolitica 
infection is iron overload, the treatment with DFOB is 
of considerable importance because of the use of 
DFOB-chelated iron by the pathogenic yersiniae [16]. 
The mechanism of virulence and growth promotion of 
these bacteria by iron provision is complicated [25,26]. 
DFOB accumulates intracellularly in eukaryotic cells 
and inhibits iron incorporation into ferritin and heme 
[37-29]. Furthermore, DFOB may inhibit proliferation 
of B- and T-lymphocytes by arresting these cells in the 
S phase of division [30-32] and DFOB and iron may 
influence phagocytic functions, such as the killing of 
microorganisms [33-35]. Patients with iron overload, 
such as the multitransfused P-thalassemic individuals, 
exhibit impaired neutrophil defense against 1: entero- 
colificu, suggesting that iron overload per se causes a 
polymorphonuclear leukocyte (PMNL) impairment, 
probably as a result of excess production of oxidative 
radicals by overstimulation of the Haber-Weiss reaction 
[36]. This process may lead to membrane breakdown 
and phagocytosis defects [33,34,37]. Although several 
studies point out that DFOB enhances ingestion of 
bacteria by human PMNLs [38,39], other reports 
suggest that iron chelators, such as DFOB, may reduce 
the microbicidal activity of phagocytes by reduction of 
hydroxyl radical production [35,40]. 
In addition, Yops are believed to counteract 
phagocytosis [.Ill. Yop H, a 47-51-kDa yersinia main 
plasmid-encoded protein, is known to play an essential 
role in dephosphorylating intracellular proteins in 
macrophages and thus inactivating them [42]. Further- 
more, through an unknown process, it enhances the 
resistance of 12vsinia to phagocytosis [43]. 
Another property of the Yops is their strong 
immunogenic action, as they stimulate the production 
of class-specific immunoglobulins (G, A, M), which 
appear very early, at  the onset of infection "21. The 
great advantage of these proteins in diagnostic tests-in 
contrast to the routine agglutination antigen-is their 
high specificity (no other bacteria are known to 
produce them) and their high cross-reactivity among 
the group of pathogenic yersiniae (independently of 
species and serotype) [MI. 
The pattern of the antibodies produced correlates 
well with the acute and chronic phases, the latter 
including also the postinfectious immunopathologic 
complications such as reactive arthritis and erythema 
nodosum [22,45,46]. The method first applied was the 
immunoblotting technique, with approximate sensi- 
tivity of 83% and specificity of 82%1 [46].The advantage 
of this technique is the simultaneous demonstration of 
the reacting Yop antigens. The course of seropositivity 
to certain major Yops, such as the strong immunogenic 
Yop V (41 kDa), is typical during the disease [47]. 
Antibodies of all classes (G, A, M) are detectable during 
the acute phase of yersinia infection. In uncomplicated 
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yersiniosis, IgM antibodies disappear after about 3 
months, followed by a decline of IgA, while IgG anti- 
bodies can persist for many years in significant concen- 
trations. The prolonged elevation of IgA antibodies 
indicates a persistent infection, a fact explained by the 
very short half-life of IgA. Thus chronic elevated IgA 
concentrations must be the result of chronic stimulation 
of the gut-associated lymphoid tissue (GALT) by the 
yersinia antigens [48]. 
In our study we used the simple, and technically 
less demanding, ELISA. The ELISA, like the imniuno- 
blot, is very suitable for the clear identification of 
antibodies specific for Yops [24]. Our study was 
retrospective and referred to a period of 19 years 
(1978-96) during which yersinia infections were 
diagnosed in the ~-thalasseiic patients. The fact that 
70.8% of the patients of groups 1,  2 and 3 were still 
positive for anti-Yop IgG several years after the 
infection indicates that the Yop ELISA will be a useful 
diagnostic method for epidemiologic studies (Table 3). 
Relapses were noticed in only a few of these patients, 
and occurred only during short periods after the 
primary infection. The protective role of anti-Yop 
antibodies is still under investigation. Experimental 
studies in mice show that their presence induces a 
partial protection against reinfection (391, but similar 
results have not been reported for humans. 
It  is of interest that seven out of 16 (13.8%) p- 
thalassemic patients with clinical manifestations com- 
patible with a yersinia infection but no confirniatory 
positive laboratory findings (culture or agglutination 
test) were seropositive (group 3, Table 2). These cases 
show the poor ability of the classical laboratory 
methods to detect yersinia infections [19]. Among 
patients with no signs of yersinia infection registered in 
the unit (group 5, Table 2) 9.5% were IgG positive, 
suggesting that these were cases either with an 
asymptomatic or mild course or with infections dating 
from before 1978. 
The absence of IgA and IgM class-specific anti- 
bodies in all P-thalassemic patients included in the 
study is in close Agreement with our clinical follow-up. 
All diagnosed infections were treated with antibiotics, 
and no patient, at  the time of the study (first trimester 
1997), had signs of a persistent chronic yersiniosis or of 
postinfectious imniunopathologic complications. 
Thalassemia major remains a main predisposing 
disease for the systemic form of yersiniosis. In a 
previous review [W], in six out of nine cayes of I: 
erzterocolitim sepsis in children, thalasseniia major was the 
underlying disease. In this young population the septic 
form may sometimes have a fatal outconie [51]. 
In conclusion, we wish to eniphasize the value of 
improved diagnostic laboratory methods, such as the 
determination of class-specific antibodies to Yops, for 
the diagnosis and follow-up of clinical cases, as well as 
for epidemiologic studies, particularly in high-risk 
groups. Their high specificity and sensitivity and their 
close correlation with the stage of disease and post- 
infectious complications make them the principal 
diagnostic tool in 1: eriterocolitird serology. 
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